Risultati della ricerca

Soggetti all'interno della tua ricerca.
Raffina i risultati
  1. 1
    NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines

    NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines di George D. Demetri, Robert S. Benjamin, Charles D. Blanke, Jean‐Yves Blay, Paolo G. Casali, Haesun Choi, Christopher L. Corless, Maria Dębiec‐Rychter, Ronald P. DeMatteo, David S. Ettinger, George A. Fisher, Christopher D.�M. Fletcher, Alessandro Gronchi, Peter Hohenberger, Miranda Hughes, Heikki Joensuu, Ian Judson, Axel Le Cesne, Robert G. Maki, Michael A. Morse, Alberto S. Pappo, Peter W. T. Pisters, Chandrajit P. Raut, Peter Reichardt, Douglas S. Tyler, Annick D. Van den Abbeele, Margaret von Mehren, Jeffrey D. Wayne, John Zalcberg

    Pubblicazione 2007
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  2. 2
    Dedifferentiation in Gastrointestinal Stromal Tumor to an Anaplastic KIT-negative Phenotype

    Dedifferentiation in Gastrointestinal Stromal Tumor to an Anaplastic KIT-negative Phenotype di Cristina R. Antonescu, Salvatore Romeo, Lei Zhang, Khédoudja Nafa, Jason L. Hornick, G. Petur Nielsen, Mari Mino‐Kenudson, Hsuan-Ying Huang, Juan‐Miguel Mosquera, Angelo Paolo Dei Tos, Christopher D.�M. Fletcher

    Pubblicazione 2013
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  3. 3
    Secondary Mutation Maintains the Transformed State in BaF3 Cells With Inducible BCR/ABL Expression

    Secondary Mutation Maintains the Transformed State in BaF3 Cells With Inducible BCR/ABL Expression di Kevin Klucher, David V. Lopez, George Q. Daley

    Pubblicazione 1998
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  4. 4
    Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate

    Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate di Ting-Jung Wu, Li‐Yu Lee, Chun‐Nan Yeh, Pei-Yu Wu, Tzu‐Chieh Chao, Tsann‐Long Hwang, Yi-Yin Jan, Miin‐Fu Chen

    Pubblicazione 2006
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  5. 5
    Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1

    Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1 di Yujiro Hayashi, Michael R. Bardsley, Yoshitaka Toyomasu, Srdjan Milosavljevic, Gabriella B. Gajdos, Kyoung Moo Choi, KMarie Reid‐Lombardo, Michael L. Kendrick, Juliane Bingener-Casey, Chih-Min Tang, Jason K. Sicklick, Simon J. Gibbons, Gianrico Farrugia, Takahiro Taguchi, Anu Gupta, Brian P. Rubin, Jonathan A. Fletcher, Abhijit Ramachandran, Tamás Ördög

    Pubblicazione 2015
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  6. 6
    Estudo da expressão dos genes ABCB1 e SLC22A1 e sua relação com marcadores de resposta ao mesilato de imatinibe em pacientes com leucemia mieloide crônica

    Estudo da expressão dos genes ABCB1 e SLC22A1 e sua relação com marcadores de resposta ao mesilato de imatinibe em pacientes com leucemia mieloide crônica di Douglas Vivona

    Pubblicazione 2014
    Testo Testo
    Tese/Dissertação
    Aggiungi alla lista
    Salvato in:
  7. 7
    Gastrointestinal stromal tumors: Clinical profile, pathogenesis, treatment strategies and prognosis

    Gastrointestinal stromal tumors: Clinical profile, pathogenesis, treatment strategies and prognosis di Arash Nowain, Hetal Bhakta, Shireen Pais, Gary C. Kanel, Sumita Verma

    Pubblicazione 2005
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  8. 8
    Emerging functions of c-kit and its ligand stem cell factor in dendritic cells

    Emerging functions of c-kit and its ligand stem cell factor in dendritic cells di Prabir Ray, Nandini Krishnamoorthy, Anuradha Ray

    Pubblicazione 2008
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  9. 9
    Philadelphia chromosome‐positive acute lymphoblastic leukemia

    Philadelphia chromosome‐positive acute lymphoblastic leukemia di Hun Ju Lee, James E. Thompson, Eunice S. Wang, Meir Wetzler

    Pubblicazione 2010
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  10. 10
    Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome‐positive acute lymphoblastic leukemia

    Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome‐positive acute lymphoblastic leukemia di Sima Jeha, Elaine Coustan‐Smith, Deqing Pei, John T. Sandlund, Jeffrey E. Rubnitz, Scott C. Howard, Hiroto Inaba, Deepa Bhojwani, Monika L. Metzger, Cheng Cheng, John Choi, Jeffrey Jacobsen, Sheila Shurtleff, Susana C. Raimondi, Raul C. Ribeiro, Ching‐Hon Pui, Dario Campana

    Pubblicazione 2014
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  11. 11
    The rise and fall of gatekeeper mutations? The <i>BCR‐ABL1</i> T315I paradigm

    The rise and fall of gatekeeper mutations? The <i>BCR‐ABL1</i> T315I paradigm di Don L. Gibbons, Sabrina Pricl, Hagop M. Kantarjian, Jorge E. Cortés, Alfonso Quintás‐Cardama

    Pubblicazione 2011
    Testo
    Editorial
    Aggiungi alla lista
    Salvato in:
  12. 12
    Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity

    Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity di Caroline J Sheeba, Gregory Marslin, Ann Mary Revina, Vinoth Kumar Megraj Khandelwal, K Balakumar, Jose Prakash, Gregory Franklin

    Pubblicazione 2015
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  13. 13
    Dasatinib in imatinib‐resistant or imatinib‐intolerant chronic myeloid leukemia in blast phase after 2 years of follow‐up in a phase 3 study

    Dasatinib in imatinib‐resistant or imatinib‐intolerant chronic myeloid leukemia in blast phase after 2 years of follow‐up in a phase 3 study di Giuseppe Saglio, Andreas Hochhaus, Yeow Tee Goh, Tamás Masszi, Ricardo Pasqüini, Frédéric Maloisel, Philipp Erben, Jorge E. Cortés, Ronald Paquette, M. Brigid Bradley‐Garelik, Chao Zhu, Hervé Dombret

    Pubblicazione 2010
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  14. 14
    BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase

    BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase di Timothy P. Hughes, Giuseppe Saglio, Alfonso Quintás‐Cardama, Michael J. Mauro, D-W Kim, Jeffrey H. Lipton, M. Brigid Bradley‐Garelik, Jon Ukropec, Andreas Hochhaus

    Pubblicazione 2015
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  15. 15
    Avaliação da associação dos polimorfismos C1236T, C3435T e G2677T/A no gene ABCB1 a marcadores de resposta ao mesilato de imatinibe em pacientes com leucemia mieloide crônica

    Avaliação da associação dos polimorfismos C1236T, C3435T e G2677T/A no gene ABCB1 a marcadores de resposta ao mesilato de imatinibe em pacientes com leucemia mieloide crônica di Douglas Vivona

    Pubblicazione 2011
    Testo Testo
    Tese/Dissertação
    Aggiungi alla lista
    Salvato in:
  16. 16
    Gastrointestinal stromal tumors: what do we know now?

    Gastrointestinal stromal tumors: what do we know now? di Christopher L. Corless

    Pubblicazione 2014
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  17. 17
    BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate–treated patients with CML

    BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate–treated patients with CML di Richard D. Press, Zac Love, Ashlie Tronnes, Rui Yang, Thuan V. Tran, Solange Mongoue‐Tchokote, Motomi Mori, Michael J. Mauro, Michael W. Deininger, Brian J. Druker

    Pubblicazione 2006
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  18. 18
    Presentation and Management of Gastrointestinal Stromal Tumors of the Duodenum

    Presentation and Management of Gastrointestinal Stromal Tumors of the Duodenum di Robert D. Winfield, Steven N. Hochwald, Stephen B. Vogel, Alan W. Hemming, Chen Liu, William G. Cance, Stephen R. Grobmyer

    Pubblicazione 2006
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  19. 19
    Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib

    Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib di Iris Amitay‐Laish, Salomon M. Stemmer, Mario E. Lacouture

    Pubblicazione 2011
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  20. 20
    Pediatric gastrointestinal stromal tumors and leiomyosarcoma

    Pediatric gastrointestinal stromal tumors and leiomyosarcoma di Monica S. Cypriano, Jesse J. Jenkins, Alberto S. Pappo, Bhaskar N. Rao, Najat C. Daw

    Pubblicazione 2004
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: